ArticleFrontiers in oncology2025
An implantable, intracerebral osmotic pump for convection-enhanced drug delivery in glioblastoma multiforme.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of local convection enhanced delivery of chemotherapy using an intracerebral osmotic pump in a rat model of glioblastoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma multiforme (GBM; WHO Grade 4) is an aggressive brain tumor that invariably recurs after surgical resection, chemoradiation, and adjuvant chemotherapy. Treatment is limited, in part, because the blood-brain barrier (BBB) restricts entry of chemotherapeutic agents to the brain. Introducing drugs directly into the brain circumvents the BBB, but diffusion of these typically large drug molecules within brain parenchyma is limited. Convection-enhanced delivery (CED), based on the principles of bulk flow, can achieve drug distribution over a wider area to target residual cancer cells and thus remains a promising technique for treating GBM and other neuro-oncologic pathologies. Here, we propose a new method that combines direct brain delivery and CED using a fully implantable, microfluidic pump placed at the time of initial resection surgery. Methods: In this initial proof-of-concept study, we evaluated the function of a 3D-printed pump in an Results: Conclusion: This preliminary study demonstrated the feasibility of using an implantable, osmosis-driven pump to bypass the BBB and provide targeted delivery for treatment of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.